CommercialCoverageMedium impact
Fluticasone HFA has been added to all BCBSRI commercial formularies
Blue Cross Blue Shield of Rhode Island·RI · Pulmonology, Allergy & Immunology, Family Medicine +2 more·Physician
Effective date
Apr 1, 2024
We identified it
Jun 19, 2026
Summary
BCBSRI has added Fluticasone HFA to all commercial formularies as a preferred tier medication, effective retroactively to April 1, 2024. This provides an alternative inhaler option due to Flovent HFA discontinuation and Asmanex HFA supply shortages.
Action Required
Immediately: Billing team should update prescribing staff that Fluticasone HFA is now preferred tier on BCBSRI commercial plans. Notify providers that this medication can be prescribed without prior authorization concerns for BCBSRI commercial patients needing HFA inhaler alternatives to discontinued Flovent HFA or shortage-affected Asmanex HFA.